Abstract. The aim of this study was to investigate the effect of daily oral administration of calcitriol on calcium metabolism in Japanese postmenopausal women. For this purpose, we administered 0.5 mg of daily calcitriol to 18 Japanese postmenopausal women for up to 24 weeks. During the first 28 days, daily administration of 0.5 mg of oral calcitriol increased fasting serum 1,25(OH) 2 D levels significantly in 9 women (Group B) (p<0.005), while no significant change was seen in another 9 women without calcitriol administration (Group A). The first 28-day calcitriol supplement increased fasting urinary calcium excretion (urinary Ca/Cr) from 0.133 ± 0.072 to 0.171 ± 0.089 (p<0.05) and fractional excretion of calcium (FECa) without changing serum Ca 2+ . Urinary NTx/Cr excretion, an index of bone resorption, decreased significantly from 64.8 ± 24.5 to 50.3 ± 27.2 nMBCE/mMCr in Group B. Following the 28-day control period, 0.5 mg of oral calcitriol was also administered to women in Group A for another 20 weeks. At the end of the 24-week investigation period, the effects of oral calcitriol on urinary calcium excretion and bone resorption were still significant in both Group A and B. A positive correlation was found between urinary Ca/Cr and NTx/Cr excretion at the start (r = 0.657, p<0.05), but this correlation was lost by calcitriol treatment (r = 0.135). These results indicated that calcitriol supplement was effective in suppressing bone resorption in postmenopausal women, and that an increased fasting urinary calcium excretion due to calcitriol supplement was predominantly caused by increased intestinal calcium absorption in these women.
CALCITRIOL or other calcitriol analogs have been widely used for the treatment of postmenopausal osteoporosis, although vitamin D status may not be deficient in this patient group in Japan [1, 2] . In several other countries, studies demonstrated the clinical effectiveness of long-term calcitriol supplement in postmenopausal osteoporosis [3] [4] [5] [6] . While an impaired intestinal calcium absorption is partly responsible for postmenopausal osteoporosis [3, 4] , Riggs and Nelson successfully demonstrated that calcium absorption could be normalized by small doses of calcitriol in postmenopausal osteoporosis [5] . In a double-blind randomized parallel study lasting 24 months, Aloia et al. [6] also demonstrated that calcitriol supplements increased bone mineral content by inhibition of bone resorption. However, such information is very limited in Japanese postmenopausal women. We also do not have any knowledge how the vitamin D status affect the effectiveness of calcitriol supplement in these Japanese women. The effect of calcitriol supplement could differ among native residents from different countries, because of differences in nutritional status, gene polymorphism, exposure time to sunlight, exercise, and other life style choices [7, 8] . To date, no clinical study has confirmed the effect of calcitriol or alfacalcidol on calcium metabolism, including intestinal calcium absorption in Japanese postmenopausal osteoporotic patients.
In this study, we investigated a calcium metabolism in Japanese postmenopausal women receiving a 24-week supplement of 0.5 mg calcitriol.
Patients and Methods
The entire study was conducted during winter (mostly sunny day) between December, 2001 and June, 2002. The participants lived in the same suburban area outside of Tokyo. Eighteen postmenopausal women with their spine bone mineral density below 80% of young adult mean value by their annual health screening (46 ± 17% of Young Adult Mean Value (YAM); range, 18 to 79%) agreed to participate in this study. Six women were treated with antihypertensive regimens but none of them was treated with any medication for osteoporosis including vitamin D 3 regimens prior to the study. Informed consent was obtained from each participant and the ethics committee of Morishita Memorial Hospital approved this study. Their femoral bone mineral density was 54 ± 9% of YAM (range, 34 to 67%). Bone mineral density ranged from 0.111 to 0.478 g/cm 2 in spine and from 0.299 to 0.589 g/cm 2 in femoral neck. Mean age was 71 ± 8 y (from 57 to 85 y) and their serum creatinine level was 0.6 ± 0.1 mg/dL (0.5-0.8 mg/dL). They were randomly divided into two groups. Nine persons (Group A) were investigated during the first 28 days without calcitriol administration as a control group, while another nine persons (Group B) were administered 0.5 mg of oral calcitriol after breakfast for 28 days. Then, the same dose of calcitriol was administered to every woman in both groups for another 20 weeks. Every woman had been instructed to take at least 600 mg of calcium and 100 IU of vitamin D from a daily food by a dietician for more than 6 months prior to the study. Their laboratory data and bone mineral densities are shown in Table 1 . Blood and urine specimens (second fresh urine) were collected on the morning of day 0, 28, 84 (12th week) and 168 (24th week) after at least 12 hours of fasting. Urinary calcium and phosphorus concentration was measured within 2 hours after collection in order to avoid the precipitation of calcium products. Thus, the data on 12th and 24th week in Group A were the results of calcitriol administration for 8 and 20 weeks, respectively. Fasting blood samples were also collected for the measurement of serum 25(OH)D and 1,25(OH) 2 D level in 24 premenopausal female nurses ranging in age from 29 to 46 y (38 ± 6 y) to compare with the data from postmenopausal women on the study. Bone mineral density was measured at both the midportion of the 3rd lumbar spine from the lateral view (spine BMD) and Ward's triangle of the femoral neck (femoral BMD) by DXA (dual-energy X-ray absorptiometry; DPXL TM , Lunar Instruments Co., Ltd., Madison, WI, USA). The measurement was performed within one month of the first blood collection. The young adult mean (YAM) value and the age-control value were provided by the manufacturer.
Laboratory tests
Dietary calcium and vitamin D intake during the study were calculated based on the 3-day diet data obtained by direct interview of patients by a dietician.
Statistical analysis
All results are presented as the mean ± standard deviation. Comparison of the result before treatment and after treatment was done by paired Student's t-test for parametric data and analysis of variance (ANOVA) was employed for the nonparametric data. Similarities between two groups were examined by non-paired t-test. Univariate regression analyses were performed to assess the relationship between each laboratory parameter of calcium metabolism. P value below 5% is considered statistically significant.
Results
The clinical data including bone mineral density of 18 postmenopausal women who entered this study are presented in Table 1 . There were no significant differences between the parameters measured in the two groups of women. Their total dietary calcium intakes were estimated from 293 mg to 1134 mg. Serum 25(OH)D level correlated positively with calculated dietary vitamin D intake (r = 0.488, p<0.05, n = 18). Serum 25(OH)D level was actually higher in 18 postmenopausal women (45 ± 15 nmol/L) than in 24 premenopausal women (38 ± 13 nmol/L, p<0.05), although serum 1,25(OH) 2 D level was not different between these two groups (140 ± 37 vs 135 ± 30 pmol/L, post-vs pre-menopausal). Vitamin D insufficiency (serum 25(OH)D level <30 nmol/L) was suspected in 2 of postmenopausal women and 9 in premenopausal women. Serum 1,25(OH) 2 D levels were inversely correlated with serum PTH level in these postmenopausal women (r = 0.635, p<0.01) as well as in these premenopausal women (r = 0.534, p<0.01). There was no The effects of 28-day administration of oral calcitriol on blood and urinary parameters are summarized in Table 2 . Daily administration of 0.5 mg of oral calcitriol increased serum 1,25(OH) 2 D levels significantly (p<0.005) and serum intact PTH level decreased significantly (p<0.05, Fig. 1A ). Blood ionized Ca 2+ , serum total Ca, phosphorus and magnesium level did not change during the first 28 days. There was no significant change in any of the parameters during the first 28-day control period in Group A as depicted in Table 3 .
Fasting urine parameters changed after 28-day calcitriol administration (Table 2 ). Urinary Ca/Cr (UCa/UCr) increased during 28-day administration of calcitriol (Fig. 1B, p<0 .05). FECa also increased significantly in calcitriol group (p<0.05). There was no significant change in TRP in either group (Fig. 1C) . Urinary NTx/Cr, an index of bone resorption, decreased significantly in the calcitriol group (p<0.001). Serum bone-specific alkaline phosphatase (BAP) level did not change significantly in either group (Table 2  and 3) .
Oral calcitriol was also given to women in Group A after 28-day observation without calcitriol. Serum calcium level, urinary Ca/Cr and urinary NTx/Cr excretion were measured in both groups on the 12th (8-week administration in Group A) and 24th week (20-week administration in Group A) from the start. Serum calcium level did not change significantly during 24-week observation in either group (Fig. 2A) . Urinary Ca/Cr also increased during 12-week administration of calcitriol and was maintained at the same level until the end in both Group A and B (Fig. 2B) . Urinary Ca/Cr was higher on 12th week than on 28th day in Group B and this effect continued till 24th week (Fig. 2B) . Urinary NTx/Cr excretion was significantly lower on 24th week than on 28th day in both groups (Fig. 2C) .
In order to examine whether the change in urinary calcium excretion due to oral calcitriol was determined by the change in bone resorption, correlation analysis was performed before and after treatment. As a result, significant positive correlation was found between urinary Ca/Cr and urinary NTx/Cr excretion before treatment (r = 0.657, p<0.01, n = 18) but the correlation lost its significance after 24-week treatment (r = 0.135, ns, n = 15) as shown in Fig. 3 .
Discussion
Daily supplements of 0.5 mg of calcitriol increased fasting serum 1,25(OH) 2 D level in Japanese postmenopausal women. As a result of calcitriol supplement, urinary NTx excretion, an index of bone resorption, was significantly reduced without changing serum bone-specific alkaline phosphatase level, an index of bone formation, at the end of the 28-day treatment time, and these effects were sustained during another 20-week administration. Calcitriol supplement increased fasting urinary excretion of calcium without changing serum calcium or phosphorus level during the 28 day investigation period. These results agreed well with the results of several long-term double-blind randomized mass studies in other countries [6, [9] [10] [11] . Gallagher demonstrated that long-term therapy on an average dose of 0.675 mg/day with 600 mg of calcium intake did not cause further increase in urinary calcium excretion and was effective in maintaining bone mineral density [9] , which opposed other studies which concluded that smaller doses of calcitriol were not effective in maintaining bone mineral density [10, 12] . Tilyard et al. also succeeded in decreasing the risk of fracture by the administration of 0.5 mg calcitriol supplement for 3 years in comparison with 1000 mg daily calcium supplement [11] . Nakamura analyzed these controlled studies and concluded that the unsuccessful outcome of active vitamin D 3 treatment was brought on by an insufficient dose [8] . Unlike the effect on calcium excretion, there was no significant change in urinary phosphorus excretion in this study. These postmenopausal women showed even higher serum 25(OH)D level and normal 1,25(OH) 2 D level but still showed higher urinary NTx excretion in this study. Since urinary NTx excretion is a good marker for bone resorption [13] , bone resorption was considered to increase in these women, even though their vitamin D status seemed to be sufficient. Since serum PTH level during calcitriol supplement decreased significantly, secondary hyperparathyroidism due to a defect in vitamin D action might be involved in a pathogenesis of increasing bone resorption besides an estrogen deficiency [14] . Additionally, we did not find a decreased level of serum 25(OH)D nor 1,25(OH) 2 D in these postmenopausal women even in wintertime (which is mostly sunny on the Pacific side of Japan). However, since serum PTH level was inversely correlated with serum 1,25(OH) 2 D level in these women, impaired calcitriol action might cause secondary hyperparathyroidism and increased bone resorption. It is also reasonable to assume in this study that calcitriol administration increased the number of vitamin D receptors and improved the action of calcitriol [15] .
Both in a previous study [2] and in this study, serum 25(OH)D levels were reported to be influenced largely by food intake in Japanese women. As a matter of fact, there was a significant positive correlation between dietary vitamin D intake and serum 25(OH)D level. Nakamura et al. measured serum 25(OH)D level in 151 postmenopausal women in wintertime and found the mean 25(OH)D concentration of 59.9 ± 17.0 nmol/L(2). Vitamin D insufficiency (<30 nmol/ L) was found in 4.6% of the women, a value lower than that found in Caucasian populations [2] . Since their population resided in the southern part of Japan and the assays were not performed in same laboratory, we cannot simply compare their result with ours. However, these two studies agree on the fact that dietary vitamin D intake influences serum 25(OH)D level. In our study, the serum level was even higher in postmenopausal women than in premenopausal women from the same area. The main reason for this discrepancy may be because the postmenopausal women had been under the instruction of dieticians for sometime ago. At any rate, the most important conclusion to be derived from this point is that calcitriol was effective in improving calcium metabolism even in persons who were not insufficient in vitamin D status.
Twenty-eight day supplements of 0.5 mg of calcitriol significantly increased fasting urinary calcium excretion (Ca/Cr) and fasting fractional calcium excretion (FECa), while serum ionized calcium did not change. Since urinary NTx excretion (a bone resorption index) decreased without changing bone-specific alkaline phosphatase (a bone formation index), the observed increased urinary calcium excretion likely resulted from increased intestinal calcium absorption. In fact, a significant positive correlation between urinary NTx/Cr excretion and urinary Ca/Cr excretion before treatment (r = 0.657, p<0.01) was blunted after calcitriol supplements (r = 0.135, ns). These results also support a role of calcitriol supplement to increase both intestinal calcium absorption and urinary calcium excretion. Need et al. [3] measured intestinal calcium absorption using 45 Ca. They demonstrated that the intestinal calcium absorption by calcitriol supplement positively correlated with urinary Ca/Cr and was inversely correlated with urinary hydroxyproline excretion, an index of bone resorption [3] . Gallagher [9] conducted a double-blind randomized study with a protocol that called for increasing the dose of 1,25(OH) 2 D 3 until patients developed either hypercalcemia or hypercalciuria. From these results, Gallagher determined that increased 1,25(OH) 2 D 3 -dependent intestinal calcium absorption leads to hypercalcemia [9] . With a daily intake of 600 mg calcium, an average dose of 0.675 mg/day 1,25(OH) 2 D 3 was the cut-off dose that prevented either hypercalcemia or nephrotoxicity [9] . Our studies in Japanese postmenopausal women supported these reports that calcitriol supplement increased intestinal calcium absorption and urinary calcium excretion. This study also confirmed that daily treatments with 0.5 mg of calcitriol were well tolerated by Japanese postmenopausal women who consumed an average of 600 mg of daily calcium intake during the 28 day investigation.
In conclusion, daily oral administration of 0.5 mg calcitriol for 28 days increased fasting serum 1,25 (OH) 2 D level without changing serum 25(OH)D level. This treatment was successful in increasing intestinal calcium absorption and reducing bone resorption without increasing serum calcium level in Japanese postmenopausal women during 6-month administration. Measuring urinary Ca/Cr in a second fresh urine sample is a good marker to assess intestinal calcium absorption which was increased by oral calcitriol treatment in postmenopausal Japanese women.
